Completed PHASE2 INTERVENTIONAL NCT00001482

New Drugs in the Treatment of Mood Disorders

Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders

Sponsor: National Institute of Mental Health (NIMH)

Conditions Anxiety Disorder Mood Disorder Psychotic Disorder

Interventions Gabapentin (Neurontin® (Registered Trademark)) Lamotrigine (Lamictal® (Registered Trademark)

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: May 31, 1995 Completion: May 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anxiety Disorder and Mood Disorder and is currently completed. National Institute of Mental Health (NIMH) leads this study, which shows 5 recorded versions since 1995 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States